Background

A hallmark of all cancer cells is their sustained proliferation, which is caused by pathogenic activation of oncoproteins and the inactivation of tumor suppressor proteins. Protein phosphatase 2A (PP2A) comprises a large family of phosphoserine/-threonine specific trimeric holoenzymes, several of which act as tumor suppressors. The assembly of these PP2A tumor-suppressive holoenzymes is dependent on the carboxy-terminal methylation of the PP2A catalytic subunit (methyl-PP2A) and thus themethyl-PP2A levels correlate with the level of PP2A tumor-suppressive phosphatase activity in cells. Since PP2A function is often impaired in human diseases such as cancer and Alzheimer, novel therapeutic approaches aim to restore PP2A activity in diseased tissue.

Technology Overview

Researchers generated the mouse monoclonal antibody 7C10-C5, the worldwide only antibody specific for the carboxy-methylated catalytic subunit of PP2A. Monoclonal antibody 7C10-C5 has excellent properties in various research and diagnostic applications including the immunohistochemical detection (IHC) of methyl-PP2A in tissue specimen (). 7C10-C5 can be used to assess methyl-PP2A levels in cancer tissue to diagnose the stage and subtype of disease, to prognose disease progression and, in the future, to predict and monitor the therapeutic response toPP2A re-activating drugs that are currently developed.

Benefits

Unique methyl-PP2A specificity

Applications

Excellent properties in various diagnostic applications including IHC

Monoclonal Antibody 7C10-C5 Specific for the Novel Cancer Biomarker Methyl-Protein Phosphatase 2A

Patents

IP Status